Education Opportunities with the Society of Naval Architects

Society of Naval Architects pic
Society of Naval Architects

In 1990 Daniel “Dan” Farber founded the military spare parts manufacturing and distribution company Bright Lights USA. Today Dan Farber is president and chief executive officer of New Jersey-based Bright Lights USA. Mr. Farber is a member of the Society of Naval Architects and Marine Engineers (SNAME).

The Society of Naval Architects and Marine Engineers is among the worlds leading nonprofit maritime and ocean professional organizations. Over 6,000 members in 85 countries work to advance industry education, networking, and research. Open to anyone studying or professionally involved in the vessel life cycle, the society offers scholarships and a variety of education courses.

Scholarships are given to high-performing undergraduate and graduate students studying marine engineering naval architecture. For experienced professionals, the society offers continuing professional education programs at its annual meeting. SNAME also offers a distance learning review course for the Professional Engineer Principles and Practice Examination in Naval Architecture and Marine Engineering.

ALS Foundation Meets with Congress on Dormant Therapies Act

ALS Foundation pic
ALS Foundation

In 1990, Daniel “Dan” Farber founded Bright Lights USA, Inc., located in Barrington, New Jersey. He serves as president and chief executive officer of Bright Lights, which manufactures and distributes spare military parts. When not in the office, Dan Farber supports several nonprofit institutions, including the ALS Association.

As the major nonprofit organization in the country fighting Lou Gehrig’s Disease, the ALS Association strives to find new treatments and a cure. It offers assistance for those afflicted with ALS, provides funding for global research, and educates the public on the disease.

To commemorate ALS awareness month (May), the ALS Association joined Congressman Leonard Lance (R-NJ), along with ALS representatives from the National Health Council for a press conference on Capitol Hill. The goal was to urge Congress to enact the Dormant Therapies Act to spur the development of treatment for diseases such as ALS. According to the Association, treatments for ALS are not in active development due to weak patents or lost patent protection. This Act would create a new category of drugs, called dormant therapies, that show potential promise. Drug manufacturers would receive an incentive to develop these drugs in the form of 15 years of marketing exclusivity for them, but would waive patent rights at the conclusion of the period.